# Cannabis Use and Outcomes in Cyclical Vomiting Syndrome: A Matched Analysis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-cyclical-vomiting-outcomes-healthcare-impact/ > **Published:** 2026-04-27T08:02:39-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:03:08-04:00 > **Clinical Summary:** Explore how cannabis use cyclical vomiting outcomes affect healthcare utilization and patient prognosis in this detailed propensity matched analysis. --- CED Clinical Relevance  #71Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic Journal Neurogastroenterology and motility Study Type Cohort Population Human participants Why This Matters This item covers developments relevant to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Clinicians monitoring evidence in this area should review the source material. Clinical Summary Cyclical Vomiting Syndrome (CVS) poses a significant financial burden on the healthcare system due to frequent emergency department (ED) visits and hospitalizations. Data on the impact of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in CVS is conflicting. This study evaluates the impact of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) on outcomes in individuals with CVS using real-world data. A retrospective cohort study was conducted using the TriNetX research network to identify adults (≥ 18 years) with CVS. Patients were categorized into two groups: CVS with cannabis use and CVS without cannabis use (controls). Using propensity score matching on demographics, body mass index, comorbidities and treatments (e.g., abortive and prophylactic therapy) cohorts were matched 1:1. Outcomes included all-cause ED visits and hospitalizations. A total of 18,588 individuals with CVS and cannabis use were matched with 18,588 individuals with CVS who did not use cannabis (controls). Cannabis users were younger (mean age [SD]: 31.9 [12.5] vs. 39.0 [19.9] years) an Dr. Caplan’s Take “This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.” Clinical Perspective 🧠 Clinicians should review this item in the context of their current practice and patient population. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Use%20Is%20Associated%20With%20Increased%20Healthcare%20Utilization%20and%20Poorer%20Outcomes%20in%20Cyclical%20Vom...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-is-associated-with-increased-healthcare-utilization-and-poorer%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-is-associated-with-increased-healthcare-utilization-and-poorer%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Use%20Is%20Associated%20With%20Increased%20Healthcare%20Utilization%20and%20Poorer%20Outcomes%20in%20Cyclical%20Vom...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcannabis-use-is-associated-with-increased-healthcare-utilization-and-poorer%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41935343/](https://pubmed.ncbi.nlm.nih.gov/41935343/) Table of Contents - [FAQ](#FAQ)[Why study cannabis use in people with cyclical vomiting syndrome?](#Why_study_cannabis_use_in_people_with_cyclical_vomiting_syndrome) - [What kind of study was this, and what outcomes did it track?](#What_kind_of_study_was_this_and_what_outcomes_did_it_track) - [How did researchers make the cannabis and non-cannabis groups comparable?](#How_did_researchers_make_the_cannabis_and_non-cannabis_groups_comparable) - [How many patients were included in the matched analysis?](#How_many_patients_were_included_in_the_matched_analysis) - [Related](#Related) ## FAQ ### Why study cannabis use in people with cyclical vomiting syndrome? Cyclical vomiting syndrome places a significant financial burden on the healthcare system because of frequent emergency department visits and hospitalizations, and existing data on how cannabis use affects the condition are conflicting. This study set out to evaluate the impact of cannabis use on outcomes in people with CVS using real-world data. ### What kind of study was this, and what outcomes did it track? It was a retrospective cohort study using real-world data from the TriNetX research network to identify adults aged 18 and older with cyclical vomiting syndrome. Patients were split into those who used cannabis and those who did not, and the outcomes compared were all-cause emergency department visits and hospitalizations. ### How did researchers make the cannabis and non-cannabis groups comparable? They used propensity score matching, pairing patients 1:1 on demographics, body mass index, comorbidities and treatments, such as abortive and prophylactic therapy. The control group consisted of adults with cyclical vomiting syndrome who did not use cannabis. ### How many patients were included in the matched analysis? The study matched 18,588 people with cyclical vomiting syndrome who used cannabis with 18,588 people with the condition who did not use cannabis. The article also reports that the cannabis users were younger, with a mean age of 31.9 years compared with 39.0 years. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Explore recent findings on cannabis and its effects on various [patient outcomes](https://cedclinic.com/uk-medical-cannabis-chronic-pain-outcomes-patient-insights/) to stay informed on emerging [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/). [Read More](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) [Preoperative Cannabis Use and Postoperative Delirium in Older Adults Undergoing Major …](https://cedclinic.com/preoperative-cannabis-use-older-adults-postoperative-delirium/) Review the impact of cannabis use on postoperative delirium in older adults, highlighting important considerations for surgical care. [Learn More](https://cedclinic.com/preoperative-cannabis-use-older-adults-postoperative-delirium/) [What Cannabis Does to Your Brain in the First 24 Hours – Verywell Health](https://cedclinic.com/cannabis-brain-effects-evidence-first-24-hours/) Understand the immediate neurological effects of cannabis use within the first 24 hours to better grasp its clinical implications. [Discover More](https://cedclinic.com/cannabis-brain-effects-evidence-first-24-hours/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).